Bionomics is an Australian biopharmaceutical company that is focused on innovating better treatments for disorders such as depression, anxiety, and Alzheimer’s disease.
Bionomics
Bionomics has a portfolio of clinical development with promising drug candidates that are in their early and mid stages. Their portfolio is fed by drug discovery platforms, including MultiCore®, the company’s own proprietary chemistry capability.
The company’s aim is to find answers for diseases that have a “high unmet need and inadequate treatment options.” Bionomics also has a strategic partnership with big pharmaceutical companies for later stages of their drug development programs and getting the said drugs into the market.
“Creating innovative therapies for serious central nervous system disorders.”
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates